

## **Brief Biographies of Some of the Speakers**

### **12<sup>th</sup> International Thyroid Cancer Survivors' Conference**

**October 16 – 18, 2009**

**Boston, Massachusetts**

**Sponsored by ThyCa: Thyroid Cancer Survivors' Association, Inc.**

**Conference details at [www.thyca.org](http://www.thyca.org)**

**Erik Alexander, M.D.**, Endocrinologist, is a thyroid specialist and medical educator at the Brigham & Women's Hospital and Harvard Medical School in Boston, Massachusetts. Dr. Alexander actively sees patients with thyroid nodules and thyroid cancer, and pursues clinical research on these topics. A separate area of interest is thyroid illness during pregnancy. Dr. Alexander has authored numerous papers, reviewed articles related to thyroid illness, and is a strong supporter of patient advocacy groups such as ThyCa: Thyroid Cancer Survivors' Association. Dr. Alexander is also the Director of Medical Student Education at the Brigham & Women's Hospital, where he oversees the education for more than 200 Harvard Medical Students annually. Dr. Alexander is a nationally invited speaker. Recent engagements have included lectures in Washington, DC, Portland, San Francisco, Chicago and Baltimore, as well as Madrid, Spain."

**Pamela M. Ayotte, CTRS/L**, is a Recreation Therapist and the Team Leader for the Therapeutic Recreation Department at Northeast Rehabilitation Hospital in Salem, New Hampshire. She is responsible for all aspects of inpatient care. She is a member of the American Therapeutic Recreation Association and a member and New Hampshire State Liaison of New England Therapeutic Recreation. She holds certifications as a Brain Injury Specialist and as an Aquatic Exercise Leader for the Arthritis Foundation. She is also pursuing master's level studies in management and health care administration at New England College.

**Zahid H. Bajwa, M.D.**, is an Anesthesiologist from Harvard Medical School. He is the Director of Education and Clinical Pain Research at the Beth Israel Deaconess Medical Center in Boston, Massachusetts. He will speak and answer questions about Pain Management and Palliative Care.

**Andrew J Bauer, M.D., LTC MC USA**, is Associate Professor of Pediatrics at the Uniformed Services University, Bethesda Maryland. He is program director for the tri-service Pediatric Endocrinology fellowship program at USU and as chief of the combined Pediatric Endocrinology service at Walter Reed Army Medical Center, Washington, DC, and National Navy Medical Center, Bethesda, MD. He received his medical degree from the State University of New York at Buffalo School of Medicine. His research areas of interest include pediatric thyroid nodular disease and cancer. He serves on the American Academy of Pediatrics Committee for Pediatric Research, the American Thyroid Association's surgical Task force and the recently formed ATA Task Force on Childhood Thyroid Cancer Treatment Guidelines. He co-authored the chapter titled "Thyroid Cancer in the Child and Adolescent" in the patients' reference book "Thyroid Cancer: A Guide for Patients."

**Dorothy Beazley, DO**, is a gynecologist/obstetrician and faculty member at Tufts Medical Center in Boston, Massachusetts. A graduate of the New York College of Osteopathic Medicine, she completed postgraduate training at St. Barnabas Hospital in NY; St. Vincent's Medical Center, NY; and the University of Tennessee Health Sciences Center, Memphis, TN. Her specialties are gynecology, maternal/fetal medicine, and obstetrics.

**Diane M. Blake, M.A.**, has been working in the field of human services more than four decades. She began her career as a psychotherapist working Community Mental Health Centers in KY and NH. She has served as Executive Director for Samaritans of the Merrimack Valley (suicide prevention), Executive Director of Big Brothers/Big Sisters of Nashua, NH, and Regional Director in Prevention and Education for the American Cancer Society. For 18 years, Diane served as adjunct faculty at Springfield College, Manchester, NH. Her husband, teacher, writer, and photographer Ric Blake, M. Ed., was diagnosed with poorly differentiated follicular carcinoma (Hurthle cell) in 1995. Together, Ric and Diane have conducted workshops on cancer survivorship and end-of-life planning throughout New England, and in 2002, they were recognized for outstanding leadership and service by the New Hampshire Partnership for End of Life Care. Ric is a founding member of ThyCa and was honored as a Board Member Emeritus. For the last nine years, Diane was employed by Merrimack Valley Hospice where she served as the Bereavement Coordinator and grief counselor and educator. She has developed workshops on advance directives and facilitated grief support groups and caregiver support groups in a variety of settings. In 2002, the New England Cancer Coalition of Survivorship recognized her as the Caregiver of the Year. Diane welcomes the opportunity to share her journey as well as the insights she has gained from the stories of her many clients.

**Lewis E. Braverman, M.D.**, Endocrinologist, is Professor of Medicine at Boston University School of Medicine and Visiting Professor since 1998 at Harvard Medical School. His research and clinical interest have focused on the physiology and pathophysiology of the thyroid. He graduated from Johns Hopkins School of Medicine and completed postgraduate training at Harvard Medical Services, Thorndike Memorial Laboratory, and Boston City Hospital. He received the Robert H Williams Distinguished Leadership Award from Endocrine Society in 2007 and is a past president of the American Thyroid Association. Currently he is Editor-in-Chief of Current Opinion in Endocrinology, Diabetes and Obesity, Editorial Board member of Thyroid, and Editor-in-Chief of Endocrine Practice, the journal of the American Association of Clinical Endocrinologists.

**Glenn W. Bunting, MS, CCC-SLP**, Speech Pathologist, is the Clinical Director of the Voice and Speech Laboratory, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts. With a Masters Degree in Communication Disorders from Boston University, he has over 29 years of clinical experience in evaluating and treating patients with a wide variety of voice disorders. In addition to his clinical duties, Mr. Bunting has taught graduate level courses in voice and speech pathology at Boston University since 1985. He continues to lecture nationally on a variety of topics including the evaluation and treatment of voice disorders related to head and neck cancer.

**Naifa Busaidy, M.D.**, is an Endocrinologist and Assistant Professor in the Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, at the University of Texas, M.D. Anderson Cancer Center in Houston, Texas. She is a graduate of Baylor College of Medicine in Houston. She completed postgraduate training at The Royal Hospital and the Sultan Qaboos University Hospital, Oman; Baylor College of Medicine, Houston, Texas; and University of Texas M. D. Anderson Cancer Center, Houston, Texas. She is the author of numerous research articles and book chapters.

**Gilbert H. Daniels, M.D.**, Endocrinologist, is Professor of Medicine at Harvard Medical School and Clinical Director of the Endocrine Genetics Program at the Massachusetts General Hospital Cancer Center in Boston, Massachusetts. His primary interests are patient care and physician and patient education. He is a graduate of Harvard Medical School and completed post-doctoral training at Massachusetts General Hospital, National Institutes of Health, and University of California San Francisco. He has served on the American Thyroid Association Executive Council as well as numerous the Education Committee, which he chaired; the Distinguished Service Award Committee; the Standards of Care Committee; the Awards Committee; the Ad Hoc Committee on Thyroid Function Testing; the Clinical Affairs Committee; the Nominating Committee; and the Thyroid Orphan Drug Task Force. In 1999, Dr. Daniels received the Distinguished Clinician Award of the American College of Endocrinology.

**Henry Fardella, M.Ed.** is a graduate of St John's Seminary in Boston, Massachusetts, and received a Master's in Education from University of Massachusetts Boston and a certificate of advanced graduate study in educational administration from University of New Hampshire. He is the Pastoral Care Coordinator at Northeast Rehabilitation Hospital. He is a clinical member of the Association for clinical pastoral education, pastoral advisory council at Holy Family Hospital, New Hampshire Chaplains Association, and chaplains peer group at Holy Family Hospital.

**Joan Fardella, M.Ed.** is a graduate of University of Massachusetts Lowell, and received a Masters in Education from Wheelock College in Boston. She was an educator for over 25 years. She is the Director of Volunteers for Rockingham VNA and Hospice, and has led bereavement groups, as well as training for the Samaritans. She also has served as a CASA volunteer for children in need, directed the Senior Companion Program, and is a member of the Board of trustees for the Kelley Library in Salem, New Hampshire.

**Alan P. Farwell, M.D.**, Endocrinologist, is Associate Professor of Medicine at Boston University School of Medicine as well as Director of Endocrine Clinics at Boston Medical Center. A graduate of the University of Massachusetts Medical School, he completed his residency in Internal Medicine at the Medical Center Hospital of Vermont and Fellowship/Post Residency in Endocrinology at the University of Massachusetts Medical Center. His main clinical and research interest are the etiology and treatment of thyroid disorders including thyroid ultrasonography and ultrasound-guided thyroid biopsies. He has a particular interest educating the public and patients about the management of thyroid disorders. He is Associate Editor of the journal *Thyroid*, as well as Director of Patient Education for the American Thyroid Association.

**Robert F. Gagel, M.D.**, Endocrinologist, is Director, Division of Internal Medicine, and Professor, Department of Endocrine Neoplasia and Hormonal Disorders at the University of Texas M.D. Anderson Cancer Center in Houston, as well as Adjunct Professor at Baylor College of Medicine. A graduate of Ohio State University Medical School, he completed postgraduate training at Tufts-New England Medical Center, Harvard Medical School, and Harvard School of Public Health. He is a frequent faculty member at continuing medical education meetings, serves on numerous committees and advisory groups for professional organizations, and has authored hundreds of peer-reviewed journal articles and other publications. Dr. Gagel's studies have focused on transcriptional regulation of the calcitonin gene. He and his colleagues identified the new variant of MEN2. Dr. Gagel has also been active in studies of the development of strategies for treatment of medullary thyroid carcinoma. He is a member of ThyCa's Medical Advisory Council.

**Margot Gibbs, M.A.**, Licensed Psychotherapist, is in private practice in Nashua, New Hampshire. She has been involved professionally in the work of facilitating growth and healing with individuals, couples and groups, in many settings over many years. Margot deeply honors the place that loss and grief hold in all of our life experience and trusts that we must learn to face and grieve our many losses/life changes, ordinary and extraordinary, to be free to live fully in the present moment.

**Jan Halzel, Pharm.D.**, is a Pharmacist who lives in Colorado. She is the co-moderator of ThyCa's Medullary Thyroid Cancer E-mail Support Group and is involved in developing the Medullary Thyroid Cancer Site on ThyCa's web site. She also represents ThyCa at medical association meetings. She earned her bachelor's degree in pharmacy at the University of Rhode Island and her doctoral degree at the University of Colorado Health Sciences Center. She is a member of ThyCa's Medical Advisory Council.

**Yariv Houvras, M.D., Ph.D.**, is a Medical Oncologist at the Massachusetts General Hospital Cancer Center in Boston, Massachusetts, where thyroid cancer is his main clinical focus. He is also an instructor at Harvard Medical School and holds a research fellowship at Children's Hospital and Howard Hughes Medical Institute at Harvard Medical School. Dr. Houvras earned his MD and PhD Degrees at Mount Sinai School of Medicine, New York, NY. His postdoctoral training included a Residency in Internal Medicine at Massachusetts General Hospital and a Fellowship in Hematology and Oncology at Massachusetts General Hospital/Dana-Farber Cancer Institute. In 2007-2008 he received a Young Investigator Award from the American Society of Clinical Oncology.

**Stephen Huang, M.D.**, is an Endocrinologist at Children's Hospital Boston, Boston, Massachusetts, as well as Assistant Professor of Pediatrics at Harvard Medical School. He directs the thyroid program at Children's Hospital and is a staff physician at Dana Farber Cancer Institute. He is the recipient of numerous awards and honors including clinical and research fellowships and a clinical scientist development award. Dr. Huang graduated from the University of Pennsylvania School of Medicine and completed postdoctoral training at Children's Hospital Boston as well as Brigham and Women's Hospital.

**Paul R. Krakovitz, M.D.**, is an Otolaryngologist at the Cleveland Clinic Foundation, Cleveland, Ohio. He is a staff member of the Head and Neck Institute and the Division of Pediatrics at the Cleveland Clinic Foundation. A graduate of Indiana University School of Medicine, he completed further training in surgery and pediatric otolaryngology at the University of Vermont, the Dartmouth Hitchcock Medical Center, and the Cleveland Clinic Foundation. He is an invited reviewer for three peer-reviewed medical journals: *Otolaryngology-Head and Neck Surgery*, *American Journal of Otolaryngology*, and *The Laryngoscope*. His clinical work focuses on pediatric otolaryngology, and his research interests include minimally invasive thyroid and parathyroid surgery in children, multiple endocrine neoplasia (MEN), and the incidence of pediatric thyroid cancer. He is author of numerous peer-reviewed medical journal articles, as well as book chapters and abstracts, and is a frequent presenter at medical meetings.

**P. Reed Larsen, M.D.**, Endocrinologist, has been Professor of Medicine at Harvard Medical School Faculty since 1982, and faculty member there since 1964. He has been at the Brigham and Women's Hospital in Boston since 1975 serving as Chief of the Thyroid Division and later of the Endocrinology, Diabetes and Hypertension Division. He directs an NIH-funded laboratory studying the role of the iodothyronine deiodinases in the regulation of thyroid hormone activation and inactivation and has published over 400 original articles, reviews and chapters. He is a past president of the American Thyroid Association. Dr. Larsen received his M.D. from Columbia University, house staff training in Internal Medicine at Columbia-Presbyterian Hospital in New York City, and Endocrinology Training at the National Institutes of Health. He Co-Edited the 9<sup>th</sup>, 10<sup>th</sup> and 11<sup>th</sup> Editions of *Williams Textbook of Endocrinology* and is Editor-in-Chief of *Nature Reviews Endocrinology*. He received the William Silen Award for Lifetime Achievement in Mentoring from Harvard Medical School and in 2008 received The Endocrine Society's highest award—the Fred Conrad Koch Award.

**Stephanie L. Lee, M.D., Ph.D., F.A.C.E.**, Endocrinologist, is Associate Professor of Medicine at Boston University School of Medicine as well as Director of the Thyroid Disease Center at Boston Medical Center. She is a graduate of the University of California, San Diego, School of Medicine, and earned her Ph.D. in Physiology and Pharmacology at the University of California, San Diego. Her postgraduate training included residency at the University of California, San Diego Medical Center and Clinical Fellowship in Endocrinology and a Research Fellowship in Molecular Medicine at the New England Medical Center. Her clinical and research interests are the Etiology and Treatment of Thyroid Disease. She recently participated in writing the American Thyroid Association Evidence-based Guidelines for the diagnosis and management of thyroid nodules and cancer and was named in Boston Magazine's "Boston's Top Doctors" and the "Guide to America's Top Physicians." She is a member of ThyCa's Medical Advisory Council.

**Cheri Lindle, M.Ed.**, of Tulsa, Oklahoma, is Senior Consultant/Facilitator at Learning Unlimited Corporation. Cheri holds a Bachelor's Degree in Sociology from Oklahoma State University, and a Master's Degree in Experiential Education from Minnesota State University at Mankato. She has worked in the field of experiential training and development for 25 years. She has held positions such as challenge course facilitator with high risk youth, challenge course director at an acute care adolescent psychiatric hospital, HR Director, Senior Management Trainer, and Corporate Consultant. Cheri has taught Sociology/Psychology at Tulsa Community College, as an adjunct since 1999, and is a full time Senior Consultant/Trainer with an International Training and Development Company; Learning Unlimited Corporation. She coordinates the Volunteer Program in the neonatal intensive care unit, NICU, at Peggy V. Helmerich Women's Health Center, Hillcrest Hospital. Cheri founded the Anaplastic Thyroid Cancer E-Mail Support Group and has previously served on the Board of Directors for ThyCa: Thyroid Cancer Survivors' Association.

**Carl D. Malchoff, M.D., Ph.D.** Otolaryngologist, is Professor of Medicine in the Division of Endocrinology and Metabolism at the University of Connecticut Health Center in Farmington, Connecticut. He is lead physician and associate director of the Carol and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, and the head of the Endocrine Neoplasia Clinical Program. Dr. Malchoff received his undergraduate degree from Cornell University, his M.D. and Ph.D. degrees from the University of Rochester, New York, and his postgraduate training in Internal Medicine and in Endocrinology and Metabolism at The University of Virginia. Dr. Malchoff's primary clinical interest is in the field of endocrine neoplasia. He is the author of numerous peer-reviewed manuscripts and over 30 book chapters, and has received recognition by Best Doctors, Inc. every year since 2003.

**Donald Margouleff, M.D.**, is a Nuclear Medicine Physician at North Shore University Hospital, Manhasset, Long Island, New York. He is also Clinical Professor at New York University Langone Medical Center. He is a member of the editorial board of the journal *Clinical Nuclear Medicine*. Dr. Margouleff is a member of ThyCa's Medical Advisory Council.

**Ernest L. Mazzaferri, M.D., M.A.C.P.** is an Endocrinologist and a past President of the American Thyroid Association, as well as a member of ATA's Guidelines Task Force that developed ATA's official clinical guidelines (2006) for managing thyroid nodules and differentiated thyroid cancer. Dr. Mazzaferri is a Master of the American College of Physicians, an award given to approximately 300 people in the country. He was also a member of the Board of Directors of the American Board of Internal Medicine (ABIM) and served as Chair of the ABIM Subspecialty Board in Endocrinology. Dr. Mazzaferri had a long and distinguished career in thyroid cancer treatment and research at Ohio State University and in recent years at the University of Florida. He is a graduate of Ohio State University College of Medicine, chaired the National Cancer Center Network panel that issued guidelines for managing thyroid cancer, and is the author and editor of over 200 peer-reviewed publications as well as textbooks on endocrinology and thyroid cancer. He is the editor of *Clinical Thyroidology* and has received many awards. He wrote the foreword for the patient reference book, *Thyroid Cancer: A Guide for Patients*. Dr. Mazzaferri is a ThyCa Medical Advisor.

**Casey McDaniel** has a B.S. in Therapeutic Recreation as part of her Recreation Management Policy degree from the University of New Hampshire. As intern and volunteer with SteppingStones program she has worked with adaptive recreation groups; dance, yoga, gardening, and functional skills; and with developing individual treatment plans and therapeutic recreation assessments. She is a member of the American Therapeutic Recreation Association.

**Bryan McIver, M.D., Ph.D., F.R.C.P.**, chairs the Thyroid Group within the Division of Endocrinology at Mayo Clinic in Rochester, Minnesota; this group has more than 40 full-time Endocrine specialists. As a consultant in endocrinology, metabolism and nutrition, he has extensive experience treating patients with diseases of the thyroid, specifically those faced with aggressive cancers such as anaplastic thyroid cancer and other advanced thyroid cancers. He also runs a research lab, working on thyroid cancer genetics and on new treatments for patients with thyroid cancer. Dr. McIver has received numerous awards and honors, including the Endocrine Society Mentor Award for Outstanding Research. He graduated Summa cum Laude in Medical Sciences from the University of Edinburgh in Scotland, received his PhD in Physiology and Biophysics from the University of Vermont; and his MB ChB Faculty of Medicine at the University of Edinburgh. He is a member of the American Thyroid Association's Thyroid Cancer Guidelines Development Group and of ThyCa's Medical Advisory Council.

**David Myssiorek, M.D., F.A.C.S.**, Otolaryngologist, is also Professor of Otolaryngology at the New York University Clinical Cancer Center. He is also Secretary of the New York Head and Neck Society. Previously he was on the staff of Long Island Jewish Hospital. A graduate of New York University School of Medicine, Dr. Myssiorek did his internship at Lenox Hill Hospital and was Chief Resident at New York University/Bellevue. He is the author of numerous articles on thyroid cancer surgery and other head and neck surgery. At ThyCa conferences Dr. Myssiorek has spoken about general surgical issues and issues related to having additional neck surgeries, as well as on the causes, prevention, and solutions for voice issues. Dr. Myssiorek is a member of ThyCa's Medical Advisory Council.

**Sareh Parangi, M.D., F.A.C.S.,** is a Surgeon at Massachusetts General Hospital, Boston, Massachusetts. She is also involved in thyroid cancer research and was a recipient of one of ThyCa's Thyroid Cancer Research Grants. Dr. Parangi earned her M.D. degree at the Columbia University College of Physicians and Surgeons after graduating from Barnard College, magna cum laude and Phi Beta Kappa. She did her surgical training in endocrine surgery at the University of California, San Francisco (UCSF) with Dr. Orlo Clark. She was Chief Resident in Surgery at UCSF in 1997-98. She joined the staff of Beth Israel Deaconess Medical Center and Harvard Medical School in 1998.

**Gregory W. Randolph, M.D.,** is an Otolaryngologist, at the Massachusetts Eye and Ear Infirmary, where he directs the thyroid clinic. He is also Clinical Associate in the Division of Surgical Oncology at Massachusetts General Hospital, and Associate Professor of Otolaryngology and Laryngology at Harvard Medical School. His main clinical interest is thyroid and parathyroid surgery. He earned his medical degree with research honors at Cornell Medical College, New York, and completed postdoctoral training in otolaryngology at the Massachusetts Eye and Ear Infirmary, Boston, Massachusetts. He serves on numerous hospital and national committees, and is the author of numerous articles and book chapters, is editor of medical texts, and has contributed to practice guidelines for thyroid cancer management. He serves on the editorial board of *Head and Neck Journal*.

**Jennifer Rosen, M.D.,** Surgeon, is Assistant Professor at Boston University School of Medicine. Her research laboratory focuses on thyroid nodules, and the prediction of benign from malignant disease based on gene expression with an interest in identifying the roles, if any, these genes have on thyroid carcinogenesis. Her research also focuses on patient factors that contribute to disease recurrence, and on patient's adherence to therapy with the goal of improving survival in patients with cancer. Dr. Rosen graduated from Jefferson Medical College, followed by residency at Beth Israel Medical Center, and then a Surgical Oncology Fellowship in the Surgery Branch at the National Cancer Institute of the National Institutes of Health in Bethesda, Maryland.

**Julie A. Rosenberg, M.D.,** is a Director of Oncology Global Clinical Research for Bristol-Myers Squibb (BMS) Company in Wallingford, CT. In this capacity, she works to develop novel therapeutic initiatives for cancer patients, and leads clinical development strategy for both genitourinary and pediatric cancers. Dr. Rosenberg obtained her B.A. and M.D. degrees from the University of Missouri School of Medicine, Kansas City, MO, followed by a Pediatrics residency and Pediatric Hematology/Oncology fellowship at Baylor College of Medicine, Houston, TX. She has worked at Boehringer Ingelheim Pharmaceuticals, as an industry consultant, and as faculty member at University of Texas Southwestern Medical Center, Dallas, TX, where her research focus was on cancer survivor outcomes and childhood leukemias and lymphomas. Dr. Rosenberg has been an athlete for over 25 years, and regularly participates in cycling, hiking, Pilates, weight lifting, yoga and boxing. It is her goal to travel the world by foot and bicycle, and to encourage health and wellness by example.

**Charles Saxe, Ph.D.,** is Scientific Program Director in the Extramural Grants Department at the American Cancer Society's national home Office in Atlanta, GA. He joined the ACS in fall 2007 and has scientific responsibility for the Program in Cancer Cell Biology and Metastasis. He has served on several Cell Biology peer review committees for the National Institutes of Health and as an ad hoc reviewer for the National Science Foundation and the British Research Council. Just prior to joining the ACS he was a member of the American Cancer Society's Peer Review Committee for Cell Structure and Metastasis. He received his Ph.D. in Genetics from the University of Arizona in 1980 and did postdoctoral training at the University of Pittsburgh and University of California at San Diego, followed by a position as a Senior Staff Fellow at the National Institutes of Health in Bethesda, Maryland. He joined the faculty of Emory University in Atlanta in and became an Associate Professor of Cell Biology and a Member of the Signal Transduction unit of the Winship Cancer Institute of Emory.

**George A. Scangos, Ph.D.**, has served as a director and as Exelixis' President and Chief Executive Officer since October 1996. From September 1993 to October 1996, Dr. Scangos served as President of Biotechnology at Bayer Corporation, a pharmaceutical company, and was responsible for research, business and process development, manufacturing, engineering and quality assurance. Dr. Scangos is a member and Chairman of the board of directors of Anadys Pharmaceuticals, Inc. and Entelos, Inc. Dr. Scangos was a Post-Doctoral Fellow at Yale University and a faculty member at Johns Hopkins University. Dr. Scangos currently holds an appointment as Adjunct Professor of Biology at Johns Hopkins University. Dr. Scangos holds a BA in Biology from Cornell University and a PhD in Microbiology from the University of Massachusetts.

**Joseph Scharpf, M.D.**, specializes in otolaryngology at the Cleveland Clinic's Main Campus at the Head and Neck Institute and the Taussig Cancer Institute in Cleveland, Ohio. His interests include head and neck cancer, head and neck reconstructive surgery, thyroid and parathyroid surgery, and paranasal sinus disease. A graduate of Case Western Reserve University, he received his medical degree from the Ohio State University College of Medicine and Public Health in Columbus, Ohio. Dr. Scharpf completed his internship and residency in surgery and otolaryngology at the Cleveland Clinic in Cleveland, Ohio. His research and clinical interests led Dr. Scharpf to Iowa Hospitals and Clinics where he completed a fellowship in head and neck oncology.

**Manisha H. Shah, M.D.**, is a medical oncologist at Ohio State University, Columbus, Ohio, where she is an attending physician at the James Cancer Hospital and is involved in research and clinical trials of treatments for advanced thyroid cancer. These include studies of new treatments for medullary thyroid cancer, and for metastatic papillary and follicular thyroid cancer unresponsive to radioiodine. She is Associate Professor at Ohio State University College of Medicine, Ohio State University, and Director, of the Neuroendocrine Tumor Clinic Program at Ohio State University. She received her medical education at Smt. N.H.L. Municipal Medical College, Gujarat University, Ahmedabad, India. She completed postdoctoral training at Sheth K. M. School of Post Graduate Medicine & Research, Ahmedabad, India; Buffalo General Hospital, SUNY at Buffalo, NY; and James Cancer Hospital and Solove Research Institute at Ohio State University. She has given numerous invited lectures and published many articles. Dr. Shah is a member of ThyCa's Medical Advisory Council.

**Julie Ann Sosa, M.D., M.A.**, is an Endocrine and Oncologic Surgeon and Associate Professor of Surgery at Yale University School of Medicine, New Haven, Connecticut. She is principal investigator or co-principal investigator of studies of new drug treatments for differentiated thyroid cancer (papillary/follicular), medullary thyroid cancer, and anaplastic thyroid cancer. Following undergraduate education at Princeton University, she received a Master's degree in Human Sciences at the University of Oxford in the United Kingdom and her medical degree from Johns Hopkins University School of Medicine, Baltimore, Maryland. She received postgraduate training at Johns Hopkins Hospital in Baltimore, Maryland, as well as John Radcliffe and Churchill Hospitals, Oxford, England. She is a frequent invited lecturer and course leader/instructor for professional audiences.



**Marie T. Sullivan, R.N., M.S.N., CRRN**, is a registered nurse with extensive experience in Intensive Care and most currently in administration. She is the Vice President of Patient Care Services at Northeast Rehabilitation Hospital Network, an acute rehabilitation hospital with numerous outpatient satellites and a home health agency. Her responsibilities encompass the medical and nursing care that patients receive inclusive of a myriad of quality and financial indicators. A year and a half ago, she was diagnosed with Papillary Thyroid Cancer and underwent two surgical procedures as well as RAI 131. She writes, "My experience as a patient within the health care system has certainly given me a new perspective which I have chosen to make a part of my administrative responsibilities. It is not only the body which must heal but the spirit and mind as well. Experiencing thyroid cancer has allowed me to explore alternatives which will aid in the total healing of our patients."

**Beatriz Tendler, M.D.**, is an Endocrinologist and Assistant Professor of Medicine at the University of Connecticut Health Center, Farmington, Connecticut, where her special focus is endocrine tumors. A graduate of Central University, Venezuela, she did her residency at Michael Reese Hospital and Medical Center, Chicago, Illinois, plus fellowship training at the University of Illinois College of Medicine and University of Connecticut School of Medicine. She speaks fluent English and Spanish.

**R. Michael Tuttle, M.D.** is an Endocrinologist at Memorial Sloan-Kettering Cancer Center, New York, New York. He is also Professor of Medicine at the Joan and Sanford I. Weill Medical College of Cornell University in New York, NY. He is an active clinician and researcher specializing in the management of advanced thyroid cancer. He travels extensively both within the US and abroad lecturing on the difficult management issues in thyroid cancer. His research projects in radiation-induced thyroid cancer have taken him from Kwajalein Atoll in the Marshall Islands to the Hanford Nuclear power-plant in Washington State to regions in Russia that were exposed to fallout from the Chernobyl accident. He serves on the American Thyroid Association committee that produced the current guidelines for the management of benign and malignant thyroid nodules. He also chaired the National Comprehensive Cancer Network Thyroid Cancer Panel, and served on the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug, and as a consultant to the Chernobyl Tissue Bank. Dr. Tuttle is a member of ThyCa's Medical Advisory Council.

**Douglas Van Nostrand, M.D.**, Nuclear Medicine Physician, is Director of Nuclear Medicine of the Division of Medicine at Washington Hospital Center in Washington, DC. He is also Professor of Medicine at Georgetown University Hospital and Director of the Washington Hospital Center's continuing medical education program. He also directs research studies on I-124 versus I-131 for differentiated thyroid cancer, I-124 versus I-131 for dosimetry for metastatic thyroid cancer, and the salivary glands. Prior to joining the Washington Hospital Center staff, Dr. Van Nostrand directed nuclear medicine at Good Samaritan Hospital in Baltimore, Maryland, after serving in the U.S. Army as director of nuclear medicine at Walter Reed Army Medical Center and in the US Air Force as director of nuclear medicine at Malcolm Grow Medical Center in Washington, D.C. He has an MD degree from Emory University School of Medicine and a BS from Duke University. He has held numerous professional leadership positions, gives numerous invited lectures to professional audiences each year, has received numerous awards, and has authored or coauthored more than 100 abstracts, articles, and chapters. He also has edited and co-edited seven medical books for professionals and patients including the patients' reference *Thyroid Cancer: A Guide for Patients*, and the medical textbook co-authored with Dr. Leonard Wartofsky, *Thyroid Cancer: A Comprehensive Guide to Clinical Management*. Dr. Van Nostrand is a member of ThyCa's Medical Advisory Council.

**Lori J. Wirth, M.D.**, Medical Oncologist, is Assistant Professor in Medicine at Harvard Medical School and Medical Director of the Head and Neck Oncology Program at the Massachusetts General Hospital Cancer Center. She is also Associate Physician in the Department of Medical Oncology at Brigham and Women's Hospital. Dr. Wirth graduated from Brown University and received her MD from Columbia University College of Physicians and Surgeons in New York. She completed a residency in Internal Medicine at New York Presbyterian Hospital and then became a fellow in Medical Oncology at the Dana-Farber Cancer Institute. She is a member of the National Cancer Institute's Metastatic/Recurrent Disease Task Force/Head and Neck Steering Committee, as well as a Thyroid Cancer Guideline Panel Member of the National Comprehensive Cancer Network. Dr. Wirth has given numerous invited presentations at the regional, national, and international levels and has authored numerous publications. She is a reviewer for the American Journal of Hematology/Oncology and the Journal of Clinical Oncology, as well as an ad-hoc reviewer for several other medical journals.

###

For more information about the

12<sup>th</sup> International Thyroid Cancer Survivors' Conference,

October 16- 18, 2009,

near Boston, Massachusetts, at the Sheraton Ferncroft Hotel, Danvers, MA,

visit

**[www.thyca.org](http://www.thyca.org)**